| Title |
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, February 2016
|
| DOI | 10.1007/s10549-016-3725-z |
| Pubmed ID | |
| Authors |
Miguel Martin, Jan C. Brase, Amparo Ruiz, Aleix Prat, Ralf Kronenwett, Lourdes Calvo, Christoph Petry, Philip S. Bernard, Manuel Ruiz-Borrego, Karsten E. Weber, César A. Rodriguez, Isabel M. Alvarez, Miguel A. Segui, Charles M. Perou, Maribel Casas, Eva Carrasco, Rosalía Caballero, Alvaro Rodriguez-Lescure |
| Abstract |
There are several prognostic multigene-based tests for managing breast cancer (BC), but limited data comparing them in the same cohort. We compared the prognostic performance of the EndoPredict (EP) test (standardized for pathology laboratory) with the research-based PAM50 non-standardized qRT-PCR assay in node-positive estrogen receptor-positive (ER+) and HER2-negative (HER2-) BC patients receiving adjuvant chemotherapy followed by endocrine therapy (ET) in the GEICAM/9906 trial. EP and PAM50 risk of recurrence (ROR) scores [based on subtype (ROR-S) and on subtype and proliferation (ROR-P)] were compared in 536 ER+/HER2- patients. Scores combined with clinical information were evaluated: ROR-T (ROR-S, tumor size), ROR-PT (ROR-P, tumor size), and EPclin (EP, tumor size, nodal status). Patients were assigned to risk-categories according to prespecified cutoffs. Distant metastasis-free survival (MFS) was analyzed by Kaplan-Meier. ROR-S, ROR-P, and EP scores identified a low-risk group with a relative better outcome (10-year MFS: ROR-S 87 %; ROR-P 89 %; EP 93 %). There was no significant difference between tests. Predictors including clinical information showed superior prognostic performance compared to molecular scores alone (10-year MFS, low-risk group: ROR-T 88 %; ROR-PT 92 %; EPclin 100 %). The EPclin-based risk stratification achieved a significantly improved prediction of MFS compared to ROR-T, but not ROR-PT. All signatures added prognostic information to common clinical parameters. EPclin provided independent prognostic information beyond ROR-T and ROR-PT. ROR and EP can reliably predict risk of distant metastasis in node-positive ER+/HER2- BC patients treated with chemotherapy and ET. Addition of clinical parameters into risk scores improves their prognostic ability. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 88 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 24% |
| Student > Bachelor | 11 | 13% |
| Other | 10 | 11% |
| Student > Master | 6 | 7% |
| Student > Doctoral Student | 5 | 6% |
| Other | 19 | 22% |
| Unknown | 16 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 47% |
| Agricultural and Biological Sciences | 8 | 9% |
| Biochemistry, Genetics and Molecular Biology | 7 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 3% |
| Nursing and Health Professions | 2 | 2% |
| Other | 8 | 9% |
| Unknown | 19 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 July 2020.
All research outputs
#6,247,869
of 22,851,489 outputs
Outputs from Breast Cancer Research and Treatment
#1,357
of 4,659 outputs
Outputs of similar age
#87,124
of 298,866 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#10
of 70 outputs
Altmetric has tracked 22,851,489 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 4,659 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 298,866 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 70 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.